Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 1 4Phase 1/2 3

Status

Active not recruiting 3

Sponsor Class

NIH 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Tumor-Agnostic 1Lymphoid 1Breast 1

Conditions

Triple Negative Breast Neoplasms 1Neoplasm Metastasis 1Lymphoma, Mantle-Cell 1

Interventions

pembrolizumab 79Cyclophosphamide 55Specimen Handling 54Carboplatin 50fludarabine 44Nivolumab 42Magnetic Resonance Spectroscopy 42Biopsy 38Gemcitabine 37Bevacizumab 34Dexamethasone 31venetoclax 27Paclitaxel 26Injections 25Docetaxel 25atezolizumab 24Pemetrexed 24Cisplatin 24Ipilimumab 23Capecitabine 21Temozolomide 19Fulvestrant 19abemaciclib 18Rituximab 18Oxaliplatin 18Lenalidomide 18Cetuximab 18Azacitidine 18Vincristine 15Fluorouracil 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × copanlisib × 90 days × Clear all
NCT04345913 2026-05-27

Testing the Addition of Copanlisib to Eribulin in Metastatic Triple Negative Breast Cancer

National Cancer Institute (NCI)

Phase 1/2 Active not recruiting
24 enrolled 24 charts
Breast

Triple Negative Breast Neoplasms

NCT04317105 2026-05-13

Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without Ipilimumab) in Patients With Advanced Solid Cancers That Have Changes in the Following Genes: PIK3CA and PTEN

National Cancer Institute (NCI)

Phase 1/2 Active not recruiting
54 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT04939272 2026-04-20

Copanlisib and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

City of Hope Medical Center

Phase 1/2 Active not recruiting
8 enrolled
Lymphoid

Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡